BioSpace News Archive

ChromaDex and Matakana Health commit to continued sales growth in Oceania, following approval from Australian regulatory body

Eli Lilly and Company (NYSE: LLY) today announced new leadership and strategic direction in oncology R&D, combining the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Lilly in early 2019

Arecor Limited announces positive headline results for the Phase I clinical trial of its ultra-rapid acting insulin product candidate, AT247.

So-Young International Inc., the most popular online destination for discovering, evaluating and reserving medical aesthetic services in China, announced the appointment of Dr. Haipeng Zhang, also known as Feng Tang, to its board of directors.

Growth capital to support expansion of Suvoda’s clinical trial software and services

Osivax announced that it has entered into an agreement with the United States’ National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to further advance the development of its lead universal flu vaccine candidate, OVX836.

Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company developing novel therapies for people with debilitating brain disorders, today reported topline results from the pivotal Phase 3 MOUNTAIN Study evaluating the effect of SAGE-217 on depressive symptoms in adults with major depressive disorder (MDD).

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the companies have received marketing authorization from China’s National Medical Products Administration (NMPA) for LYNPARZA

Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced the appointment of biopharmaceutical industry veteran Juan Andres to its Board of Directors.

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company’s board of directors granted four new employees non-qualified stock options to purchase an aggregate of 52,500 shares of Calithera’s common stock,